Nabriva Therapeutics AG 4
4 · Nabriva Therapeutics AG · Filed May 25, 2017
Insider Transaction Report
Form 4
Talbot George Harrison
Director
Transactions
- Sale
Common Shares
2017-05-23$99.70/sh−30$2,991→ 3,854 total - Sale
Common Shares
2017-05-25$100.50/sh−205$20,603→ 3,649 total - Sale
Common Shares
2017-05-25$101.00/sh−90$9,090→ 3,559 total
Footnotes (4)
- [F1]The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares.
- [F2]The price of $99.70 per common share was derived from the sale price on May 23, 2017, of $9.97 per ADS, multiplied by ten.
- [F3]The price of $100.50 per common share was derived from the sale price on May 25, 2017, of $10.05 per ADS, multiplied by ten.
- [F4]The price of $101.00 per common share was derived from the sale price on May 25, 2017, of $10.10 per ADS, multiplied by ten.